

Leonhard MÃ¼llauer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4023224/publications.pdf>

Version: 2024-02-01

161
papers

5,924
citations

71102

41
h-index

85541

71
g-index

163
all docs

163
docs citations

163
times ranked

7885
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 3179-3184. | 1.6 | 441 |
| 2 | A prognostic model to predict survival in 867 World Health Organizationâ€‘defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. <i>Blood</i> , 2012, 120, 1197-1201. | 1.4 | 222 |
| 3 | BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. <i>Blood</i> , 2012, 120, e28-e34. | 1.4 | 199 |
| 4 | SPAG6 and L1TD1 are transcriptionally regulated by DNA methylation in non-small cell lung cancers. <i>Molecular Cancer</i> , 2017, 16, 1. | 19.2 | 196 |
| 5 | Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. <i>Blood</i> , 2011, 117, 5710-5718. | 1.4 | 163 |
| 6 | Genome-Wide Transcriptional Response to 5-Aza-2â€‘Deoxycytidine and Trichostatin A in Multiple Myeloma Cells. <i>Cancer Research</i> , 2008, 68, 44-54. | 0.9 | 157 |
| 7 | Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML). <i>Oncotarget</i> , 2012, 3, 1588-1599. | 1.8 | 144 |
| 8 | Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis. <i>Modern Pathology</i> , 2011, 24, 585-595. | 5.5 | 131 |
| 9 | Mutations in apoptosis genes: a pathogenetic factor for human disease. <i>Mutation Research - Reviews in Mutation Research</i> , 2001, 488, 211-231. | 5.5 | 130 |
| 10 | Masked polycythemia Vera (mpV): Results of an international study. <i>American Journal of Hematology</i> , 2014, 89, 52-54. | 4.1 | 130 |
| 11 | Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study. <i>Lancet Haematology</i> , 2017, 4, e595-e606. | 4.6 | 130 |
| 12 | Mucosa-Associated Lymphoid Tissue Lymphoma: Novel Translocations Including Rearrangements of <i>ODZ2</i> , <i>JMJD2C</i> , and <i>CNN3</i> . <i>Clinical Cancer Research</i> , 2008, 14, 6426-6431. | 7.0 | 127 |
| 13 | B-cell deficiency and severe autoimmunity caused by deficiency of protein kinase C Î¶. <i>Blood</i> , 2013, 121, 3112-3116. | 1.4 | 118 |
| 14 | ALK-positive anaplastic large cell lymphoma limited to the skin: clinical, histopathological and molecular analysis of 6 pediatric cases. A report from the ALCL99 study. <i>Haematologica</i> , 2013, 98, 50-56. | 3.5 | 112 |
| 15 | Diagnostic and Subdiagnostic Accumulation of Mast Cells in the Bone Marrow of Patients with Anaphylaxis: Monoclonal Mast Cell Activation Syndrome. <i>International Archives of Allergy and Immunology</i> , 2007, 142, 158-164. | 2.1 | 111 |
| 16 | Review of cancer treatment with immune checkpoint inhibitors. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 85-91. | 1.9 | 102 |
| 17 | Evaluation of Diffusion-Weighted MRI for Pretherapeutic Assessment and Staging of Lymphoma: Results of a Prospective Study in 140 Patients. <i>Clinical Cancer Research</i> , 2014, 20, 2984-2993. | 7.0 | 100 |
| 18 | Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patients. <i>Blood</i> , 2009, 114, 3854-3863. | 1.4 | 91 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: The diagnostic interface. <i>Leukemia Research</i> , 2007, 31, 1461-1468. | 0.8 | 90 |
| 20 | Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. <i>Blood</i> , 2012, 119, 2239-2241. | 1.4 | 90 |
| 21 | Molecular pathology of lung cancer: current status and perspectives. <i>Current Opinion in Oncology</i> , 2018, 30, 69-76. | 2.4 | 82 |
| 22 | A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma). <i>Haematologica</i> , 2013, 98, 353-356. | 3.5 | 81 |
| 23 | Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18F-FDG-PET/CTâ€”Controlled Prospective Study in 64 Patients. <i>Clinical Cancer Research</i> , 2015, 21, 2506-2513. | 7.0 | 78 |
| 24 | Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders. <i>Cancer Discovery</i> , 2022, 12, 372-387. | 9.4 | 77 |
| 25 | Molecular Profiling of Thymoma and Thymic Carcinoma: Genetic Differences and Potential Novel Therapeutic Targets. <i>Pathology and Oncology Research</i> , 2017, 23, 551-564. | 1.9 | 72 |
| 26 | Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer. <i>Journal of Pathology</i> , 2000, 190, 20-30. | 4.5 | 71 |
| 27 | A phase II study of bortezomib in patients with MALT lymphoma. <i>Haematologica</i> , 2009, 94, 738-742. | 3.5 | 70 |
| 28 | Genome-wide CpG island methylation analyses in non-small cell lung cancer patients. <i>Carcinogenesis</i> , 2013, 34, 513-521. | 2.8 | 67 |
| 29 | Increased copyâ€”number and not DNA hypomethylation causes overexpression of the candidate protoâ€”oncogene CYP24A1 in colorectal cancer. <i>International Journal of Cancer</i> , 2013, 133, 1380-1388. | 5.1 | 65 |
| 30 | Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412. <i>Blood</i> , 2007, 109, 3031-3041. | 1.4 | 64 |
| 31 | Masked polycythemia vera diagnosed according to WHO and BCSH classification. <i>American Journal of Hematology</i> , 2014, 89, 199-202. | 4.1 | 64 |
| 32 | Microparticleâ€”associated tissue factor activity in patients with pancreatic cancer: correlation with clinicopathological features. <i>European Journal of Clinical Investigation</i> , 2013, 43, 277-285. | 3.4 | 59 |
| 33 | <i>Helicobacter pylori</i> eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trial. <i>Blood</i> , 2012, 120, 3858-3860. | 1.4 | 58 |
| 34 | Levels of transforming growth factor $\hat{1}^2$ and transforming growth factor $\hat{1}^2$ receptors in rat liver during growth, regression by apoptosis and neoplasia. <i>Hepatology</i> , 1998, 28, 717-726. | 7.3 | 56 |
| 35 | Diagnosis and Immunophenotype of 188 Pediatric Lymphoblastic Lymphomas Treated Within a Randomized Prospective Trial. <i>American Journal of Surgical Pathology</i> , 2011, 35, 836-844. | 3.7 | 54 |
| 36 | Identification of Basogranulin (BB1) as a Novel Immunohistochemical Marker of Basophils in Normal Bone Marrow and Patients With Myeloproliferative Disorders. <i>American Journal of Clinical Pathology</i> , 2006, 125, 273-281. | 0.7 | 50 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia. <i>Oncotarget</i> , 2015, 6, 3071-3084. | 1.8 | 50 |
| 38 | Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: An international study of 264 patients. <i>American Journal of Hematology</i> , 2012, 87, 669-672. | 4.1 | 49 |
| 39 | Digital PCR: A Sensitive and Precise Method for KIT D816V Quantification in Mastocytosis. <i>Clinical Chemistry</i> , 2018, 64, 547-555. | 3.2 | 49 |
| 40 | Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease. <i>American Journal of Hematology</i> , 2017, 92, 885-891. | 4.1 | 47 |
| 41 | Adenocarcinoma of the Thymus, Enteric Type. <i>American Journal of Surgical Pathology</i> , 2015, 39, 541-548. | 3.7 | 43 |
| 42 | Host Defense Mechanisms in Secondary Syphilitic Lesions. <i>American Journal of Pathology</i> , 2010, 177, 2421-2432. | 3.8 | 42 |
| 43 | Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category. <i>Leukemia and Lymphoma</i> , 2006, 47, 451-460. | 1.3 | 41 |
| 44 | Evaluation of Angiogenesis and Vascular Endothelial Growth Factor Expression in the Bone Marrow of Patients with Aplastic Anemia. <i>American Journal of Pathology</i> , 2006, 168, 123-130. | 3.8 | 40 |
| 45 | Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms. <i>FASEB Journal</i> , 2012, 26, 894-906. | 0.5 | 40 |
| 46 | Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma). <i>Annals of Hematology</i> , 2014, 93, 249-253. | 1.8 | 39 |
| 47 | Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): Detection of FIP1L1/PDGFR α , classification by WHO criteria, and response to therapy with imatinib. <i>Leukemia Research</i> , 2006, 30, 1201-1205. | 0.8 | 37 |
| 48 | Retrospective comparison of the effectiveness of various treatment modalities of extragastric MALT lymphoma: a single-center analysis. <i>Annals of Hematology</i> , 2014, 93, 1287-1295. | 1.8 | 37 |
| 49 | FAS (CD95) Mutations Are Rare in Gastric MALT Lymphoma but Occur More Frequently in Primary Gastric Diffuse Large B-Cell Lymphoma. <i>American Journal of Pathology</i> , 2004, 164, 1081-1089. | 3.8 | 36 |
| 50 | Myeloid sarcoma with multiple lesions of the central nervous system in a patient without leukemia. <i>Journal of Neurosurgery</i> , 2006, 105, 916-919. | 1.6 | 36 |
| 51 | Identification of Oncostatin M as a STAT5-Dependent Mediator of Bone Marrow Remodeling in KIT D816V-Positive Systemic Mastocytosis. <i>American Journal of Pathology</i> , 2011, 178, 2344-2356. | 3.8 | 36 |
| 52 | Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentöse Tumortherapie. <i>Haematologica</i> , 2013, 98, 264-268. | 3.5 | 36 |
| 53 | Clinical Features, Treatment and Outcome of Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma of the Ocular Adnexa: Single Center Experience of 60 Patients. <i>PLoS ONE</i> , 2014, 9, e104004. | 2.5 | 35 |
| 54 | Expression of RAGE and HMGB1 in Thymic Epithelial Tumors, Thymic Hyperplasia and Regular Thymic Morphology. <i>PLoS ONE</i> , 2014, 9, e94118. | 2.5 | 30 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Malignant cell detection by fluorescence in situ hybridization (FISH) in effusions from patients with carcinoma. <i>Human Pathology</i> , 2000, 31, 448-455. | 2.0 | 29 |
| 56 | Fibroblast growth factor receptor 4 induced resistance to radiation therapy in colorectal cancer. <i>Oncotarget</i> , 2016, 7, 69976-69990. | 1.8 | 27 |
| 57 | DNA methylation transcriptionally regulates the putative tumor cell growth suppressor <i>ZNF677</i> in non-small cell lung cancers. <i>Oncotarget</i> , 2015, 6, 394-408. | 1.8 | 27 |
| 58 | Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients. , 2021, 9, e001458. | | 26 |
| 59 | Active cell death: role in hepatocarcinogenesis and subtypes. <i>Biochemistry and Cell Biology</i> , 1994, 72, 669-675. | 2.0 | 25 |
| 60 | Clinicopathological aspects of mucosa-associated lymphoid tissue (MALT) lymphoma of the parotid gland: A retrospective single-center analysis of 28 cases. <i>Head and Neck</i> , 2011, 33, 763-767. | 2.0 | 25 |
| 61 | Elevated CRP levels predict poor outcome and tumor recurrence in patients with thymic epithelial tumors: A pro- and retrospective analysis. <i>Oncotarget</i> , 2017, 8, 47090-47102. | 1.8 | 25 |
| 62 | CD52 is a molecular target in advanced systemic mastocytosis. <i>FASEB Journal</i> , 2014, 28, 3540-3551. | 0.5 | 24 |
| 63 | Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas. <i>Medicine (United States)</i> , 2015, 94, e2388. | 1.0 | 24 |
| 64 | CCL2 is a KIT D816V-dependent modulator of the bone marrow microenvironment in systemic mastocytosis. <i>Blood</i> , 2017, 129, 371-382. | 1.4 | 24 |
| 65 | Next generation sequencing: clinical applications in solid tumours. <i>Memo - Magazine of European Medical Oncology</i> , 2017, 10, 244-247. | 0.5 | 24 |
| 66 | A specific protein, p92, detected in flat revertants derived from NIH/3T3 transformed by human activated c-Ha-ras oncogene. <i>Experimental Cell Research</i> , 1990, 186, 115-121. | 2.6 | 23 |
| 67 | Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup. <i>Clinical Cancer Research</i> , 2020, 26, 3819-3830. | 7.0 | 23 |
| 68 | LAG-3 expression in the inflammatory microenvironment of glioma. <i>Journal of Neuro-Oncology</i> , 2021, 152, 533-539. | 2.9 | 22 |
| 69 | Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis. <i>Haematologica</i> , 2020, 105, 366-374. | 3.5 | 21 |
| 70 | Restoration of response to ruxolitinib upon brief withdrawal in two patients with myelofibrosis. <i>American Journal of Hematology</i> , 2014, 89, 344-346. | 4.1 | 20 |
| 71 | Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage. <i>Annals of Hematology</i> , 2015, 94, 223-231. | 1.8 | 20 |
| 72 | Does Delayed-Time-Point Imaging Improve 18F-FDG-PET in Patients With MALT Lymphoma?. <i>Clinical Nuclear Medicine</i> , 2016, 41, 101-105. | 1.3 | 20 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 73 | Plasmacytic differentiation in MALT lymphomas following treatment with rituximab. <i>Annals of Hematology</i> , 2012, 91, 723-728. | 1.8 | 18 |
| 74 | Can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?. <i>Clinical Nuclear Medicine</i> , 2016, 41, 837-843. | 1.3 | 18 |
| 75 | Impact of white blood cell counts at diagnosis and during follow-up in patients with essential thrombocythaemia and prefibrotic primary myelofibrosis. <i>British Journal of Haematology</i> , 2017, 179, 166-169. | 2.5 | 18 |
| 76 | Cerebrospinal Fluid Penetration and Combination Therapy of Entrectinib for Disseminated ROS1/NTRK-Fusion Positive Pediatric High-Grade Glioma. <i>Journal of Personalized Medicine</i> , 2020, 10, 290. | 2.5 | 18 |
| 77 | Functions of [His321]Gelsolin Isolated from a Flat Revertant of ras -Transformed Cells. <i>FEBS Journal</i> , 1995, 229, 615-620. | 0.2 | 18 |
| 78 | Indolent systemic mastocytosis associated with atypical small lymphocytic lymphoma: a rare form of concomitant lymphoproliferative disease. <i>Human Pathology</i> , 2008, 39, 917-924. | 2.0 | 17 |
| 79 | Rituximab Plus Dose-Reduced Cyclophosphamide, Mitoxantrone, Vincristine, and Prednisolone Are Effective in Elderly Patients with Diffuse Large B-Cell Lymphoma of the Thyroid. <i>Thyroid</i> , 2010, 20, 425-427. | 4.5 | 17 |
| 80 | Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536. <i>Haematologica</i> , 2011, 96, 672-680. | 3.5 | 17 |
| 81 | Soluble PD-L1 is associated with local and systemic inflammation markers in primary and secondary brain tumours. <i>ESMO Open</i> , 2020, 5, e000863. | 4.5 | 17 |
| 82 | Prognostic and diagnostic impact of fibrinogen, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio on thymic epithelial tumors outcome. <i>Oncotarget</i> , 2018, 9, 21861-21875. | 1.8 | 17 |
| 83 | Nonpegylated liposomal doxorubicin is highly active in patients with B and T/NK cell lymphomas with cardiac comorbidity or higher age. <i>Annals of Hematology</i> , 2010, 89, 163-169. | 1.8 | 16 |
| 84 | Identification of Basogranulin (BB1) as a Novel Immunohistochemical Marker of Basophils in Normal Bone Marrow and Patients With Myeloproliferative Disorders. <i>American Journal of Clinical Pathology</i> , 2006, 125, 273-281. | 0.7 | 16 |
| 85 | A mimic of sarcoidosis. <i>Lancet, The</i> , 2007, 369, 1832. | 13.7 | 15 |
| 86 | Programmed death-ligand 1 expression in rectal cancer. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2016, 48, 352-356. | 0.7 | 15 |
| 87 | Novel Insights into Diagnosis, Biology and Treatment of Primary Diffuse Leptomeningeal Melanomatosis. <i>Journal of Personalized Medicine</i> , 2021, 11, 292. | 2.5 | 15 |
| 88 | Immunohistochemical detection of histidine decarboxylase in neoplastic mast cells in patients with systemic mastocytosis. <i>Human Pathology</i> , 2006, 37, 439-447. | 2.0 | 14 |
| 89 | PD-L1 Expression on Tumor Cells Is Associated With a Poor Outcome in a Cohort of Caucasian Nasopharyngeal Carcinoma Patients. <i>Frontiers in Oncology</i> , 2019, 9, 1334. | 2.8 | 14 |
| 90 | Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation. <i>Frontiers in Oncology</i> , 2020, 10, 593852. | 2.8 | 14 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | t(11;14)(q23;q32) involving <i>IGH</i> and <i>DDX6</i> in nodal marginal zone lymphoma. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 33-43. | 2.8 | 13 |
| 92 | Decanucleotide insertion polymorphism of F7 significantly influences the risk of thrombosis in patients with essential thrombocythemia. <i>European Journal of Haematology</i> , 2014, 93, 103-111. | 2.2 | 13 |
| 93 | FGF8 induces therapy resistance in neoadjuvantly radiated rectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 77-86. | 2.5 | 13 |
| 94 | Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer. <i>Cancers</i> , 2020, 12, 548. | 3.7 | 13 |
| 95 | Risk Reclassification of Patients with Endometrial Cancer Based on Tumor Molecular Profiling: First Real World Data. <i>Journal of Personalized Medicine</i> , 2021, 11, 48. | 2.5 | 13 |
| 96 | TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML. <i>Oncotarget</i> , 2017, 8, 23061-23072. | 1.8 | 13 |
| 97 | Subcutaneous dissemination pattern in extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue lymphoma. <i>Haematologica</i> , 2012, 97, 766-770. | 3.5 | 12 |
| 98 | FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816H. <i>Leukemia Research Reports</i> , 2014, 3, 8-13. | 0.4 | 12 |
| 99 | Activity of Pembrolizumab in Recurrent Cervical Cancer. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1196-1202. | 2.5 | 12 |
| 100 | Follistatin impacts Tumor Angiogenesis and Outcome in Thymic Epithelial Tumors. <i>Scientific Reports</i> , 2019, 9, 17359. | 3.3 | 12 |
| 101 | Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092863. | 3.2 | 12 |
| 102 | STAT5 is Expressed in CD34+/CD38 ^{low} Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative Neoplasms. <i>Cancers</i> , 2020, 12, 1021. | 3.7 | 12 |
| 103 | Elevated gelsolin and β -actin expression in a flat revertant R1 of Ha-ras oncogene-transformed NIH3T3 cells. <i>Biochemical and Biophysical Research Communications</i> , 1990, 171, 852-859. | 2.1 | 11 |
| 104 | Reliability of Tumor Testing Compared to Germline Testing for Detecting BRCA1 and BRCA2 Mutations in Patients with Epithelial Ovarian Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 593. | 2.5 | 11 |
| 105 | Results of the extended analysis for cancer treatment (EXACT) trial: a prospective translational study evaluating individualized treatment regimens in oncology. <i>Oncotarget</i> , 2019, 10, 942-952. | 1.8 | 11 |
| 106 | Idiopathic bone marrow dysplasia of unknown significance (IDUS): definition, pathogenesis, follow up, and prognosis. <i>American Journal of Cancer Research</i> , 2011, 1, 531-41. | 1.4 | 11 |
| 107 | DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma. , 2022, 10, e003420. | | 11 |
| 108 | Extranodal marginal zone lymphoma of the CNS arising after a long-standing history of atypical white matter disease. <i>Leukemia Research</i> , 2012, 36, e155-e157. | 0.8 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Hyperdiploidy and apparent aneusomy in mesothelial cells from non-malignant effusions as detected by fluorescence in situ hybridization (FISH). , 1999, 38, 15-23. | | 9 |
| 110 | Autoimmune Lymphoproliferative Syndrome (ALPS) Caused by Fas (CD95) Mutation Mimicking Sarcoidosis. American Journal of Surgical Pathology, 2008, 32, 329-334. | 3.7 | 9 |
| 111 | Genomic alterations in thymomaâ€”molecular pathogenesis?. Journal of Thoracic Disease, 2020, 12, 7536-7544. | 1.4 | 9 |
| 112 | Pembrolizumab plus docetaxel for the treatment of recurrent/metastatic head and neck cancer: A prospective phase I/II study. Oral Oncology, 2022, 124, 105634. | 1.5 | 9 |
| 113 | Influence of TP53 Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era. Cancers, 2021, 13, 5592. | 3.7 | 9 |
| 114 | Primary mucosa-associated lymphoid tissue (MALT) lymphoma of the liver: clinical, molecular, and microbiological aspects. Annals of Hematology, 2012, 91, 1817-1818. | 1.8 | 8 |
| 115 | Clarithromycin Leading to Complete Remission in the First-Line Treatment of Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma. Journal of Clinical Oncology, 2015, 33, e130-e132. | 1.6 | 8 |
| 116 | A pilot study of confocal laser endomicroscopy for diagnosing gastrointestinal mucosa-associated lymphoid tissue (MALT) lymphoma. Surgical Endoscopy and Other Interventional Techniques, 2016, 30, 2879-2885. | 2.4 | 7 |
| 117 | Milestones in pathologyâ€”from histology to molecular biology. Memo - Magazine of European Medical Oncology, 2017, 10, 42-45. | 0.5 | 7 |
| 118 | Interim analysis of a real-world precision medicine platform for molecular profiling of metastatic or advanced cancers: MONDTI. ESMO Open, 2019, 4, e000538. | 4.5 | 7 |
| 119 | Targeted Therapy Recommendations for Therapy Refractory Solid Tumorsâ€”Data from the Real-World Precision Medicine Platform MONDTI. Journal of Personalized Medicine, 2020, 10, 188. | 2.5 | 7 |
| 120 | Short-term and sustained clinical response following thymectomy in patients with myasthenia gravis. European Journal of Neurology, 2022, 29, 2453-2462. | 3.3 | 7 |
| 121 | Recommendations of the Austrian Working Group on Pulmonary Pathology and Oncology for predictive molecular and immunohistochemical testing in non-small cell lung cancer. Memo - Magazine of European Medical Oncology, 2016, 9, 191-200. | 0.5 | 6 |
| 122 | Clinical prognostic scores for patients with thymic epithelial tumors. Scientific Reports, 2019, 9, 18581. | 3.3 | 6 |
| 123 | Heat shock protein 90Î± in thymic epithelial tumors and non-thymomatous myasthenia gravis. OncoImmunology, 2020, 9, 1756130. | 4.6 | 6 |
| 124 | Analysis of 10 Adrenocortical Carcinoma Patients in the Cohort of the Precision Medicine Platform MONDTI. Oncology, 2018, 94, 306-310. | 1.9 | 5 |
| 125 | Applied precision medicine in metastatic pancreatic ductal adenocarcinoma. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592093861. | 3.2 | 5 |
| 126 | Precision Medicine for the Management of Therapy Refractory Colorectal Cancer. Journal of Personalized Medicine, 2020, 10, 272. | 2.5 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | The 2020 update of the recommendations of the Austrian working group on lung pathology and oncology for the diagnostic workup of non-small cell lung cancer with focus on predictive biomarkers. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 11-26. | 0.5 | 5 |
| 128 | Overweight as a Favorable Clinical Biomarker for Checkpoint Inhibitor Therapy Response in Recurrent Gynecologic Cancer Patients. <i>Biomolecules</i> , 2021, 11, 1700. | 4.0 | 5 |
| 129 | Prevalence and clinical impact of autoimmune diseases and chronic infections in malignant lymphomas at diagnosis. <i>Annals of Hematology</i> , 2011, 90, 947-954. | 1.8 | 4 |
| 130 | Evaluation of efficacy of alemtuzumab in 5 patients with aplastic anemia and/or myelodysplastic neoplasm. <i>Wiener Klinische Wochenschrift</i> , 2017, 129, 404-410. | 1.9 | 4 |
| 131 | Molecular Guided Treatments in Gynecologic Oncology: Analysis of a Real-World Precision Cancer Medicine Platform. <i>Oncologist</i> , 2020, 25, e1060-e1069. | 3.7 | 4 |
| 132 | Molecularly guided treatment of metastatic parotid gland carcinoma in adults. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 32-40. | 1.9 | 4 |
| 133 | Molecular Pathology of Cancer: The Past, the Present, and the Future. <i>Journal of Personalized Medicine</i> , 2021, 11, 676. | 2.5 | 4 |
| 134 | Functions of [His321]Gelsolin Isolated from a Flat Revertant of <i>ras</i> Transformed Cells. <i>FEBS Journal</i> , 1995, 229, 615-620. | 0.2 | 3 |
| 135 | Recommendations of the Austrian Working Group on Lung Pathology and Oncology for predictive molecular and immunohistochemical testing in non-small cell lung cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2013, 6, 83-91. | 0.5 | 3 |
| 136 | <i>ROS1</i> mutation and treatment with crizotinib in a 30-year old Caucasian woman with stage <i>IV</i> non-small cell lung cancer/adenocarcinoma and complete remission. <i>Thoracic Cancer</i> , 2014, 5, 455-459. | 1.9 | 3 |
| 137 | The potential evasion of immune surveillance in mucosa associated lymphoid tissue lymphoma by DcR2-mediated up-regulation of nuclear factor- κ B. <i>Leukemia and Lymphoma</i> , 2015, 56, 1440-1449. | 1.3 | 3 |
| 138 | Signet Ring Cell Carcinoma of the Lung: A Diagnostic Pitfall in Pregnancy. <i>Case Reports in Obstetrics and Gynecology</i> , 2019, 2019, 1-8. | 0.3 | 3 |
| 139 | Rapid Clinical and Radiologic Responses With Larotrectinib Treatment in a Patient With TRK-Fusion Positive Metastatic Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, e49-e53. | 2.6 | 3 |
| 140 | Gender differences in molecularly guided therapy recommendations for metastatic malignant mesothelioma. <i>Thoracic Cancer</i> , 2020, 11, 1979-1988. | 1.9 | 3 |
| 141 | Unique Finding of a Primary Central Nervous System Neuroendocrine Carcinoma in a 5-Year-Old Child: A Case Report. <i>Frontiers in Neuroscience</i> , 2022, 16, 810645. | 2.8 | 3 |
| 142 | DIPG-60. Avapritinib for targeting PDGFRA in H3K27M mutated diffuse midline glioma. <i>Neuro-Oncology</i> , 2022, 24, i32-i32. | 1.2 | 3 |
| 143 | Tumour immune microenvironment in resected thymic carcinomas as a predictor of clinical outcome. <i>British Journal of Cancer</i> , 2022, 127, 1162-1171. | 6.4 | 3 |
| 144 | β T-cell Lymphoma Mimicking SÅzary Syndrome. <i>Acta Dermato-Venereologica</i> , 2012, 92, 166-168. | 1.3 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | Rituximab, Ara-C, dexamethasone and oxaliplatin (R-ADOx) is effective for treatment of elderly patients with relapsed mantle cell lymphoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1771-1775. | 2.5 | 2 |
| 146 | Outcome of Targeted Therapy Recommendations for Metastatic and Recurrent Head and Neck Cancers. <i>Cancers</i> , 2020, 12, 3381. | 3.7 | 2 |
| 147 | Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer. , 2000, 190, 20. | | 2 |
| 148 | Feasibility of personalized treatment concepts in gastrointestinal malignancies: Sub-group results of prospective clinical phase II trial EXACT. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2018, 30, 508-515. | 2.2 | 2 |
| 149 | Running in the family: MALT lymphoma and autoimmune disease in mother and daughter. <i>World Journal of Gastrointestinal Oncology</i> , 2012, 4, 26. | 2.0 | 2 |
| 150 | INNV-17. RESPONSE TO AVAPRITINIB IN A PEDIATRIC SPINAL CORD H3K27M-MUTANT GLIOMA PATIENT. <i>Neuro-Oncology</i> , 2021, 23, vi108-vi108. | 1.2 | 2 |
| 151 | Author's reply. <i>Journal of Pathology</i> , 2000, 191, 469-470. | 4.5 | 1 |
| 152 | FISH Technique as Additional Diagnostic Tool in Differentiating Testicular Pulmonary Metastasis from Pulmonary Congenital Cystic Adenomatoid Malformation. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2016, 24, e16-e17. | 1.2 | 1 |
| 153 | VARIFI™ Web-Based Automatic Variant Identification, Filtering and Annotation of Amplicon Sequencing Data. <i>Journal of Personalized Medicine</i> , 2019, 9, 10. | 2.5 | 1 |
| 154 | Bromodomain-Containing Protein 4 (BRD4): A Novel Marker and Drug Target Expressed In Neoplastic Cells In Advanced Mast Cell Neoplasms. <i>Blood</i> , 2013, 122, 3747-3747. | 1.4 | 1 |
| 155 | In Contemporary Patients with Polycythemia Vera, Rates of Thrombosis and Risk Factors Delineate a New Clinical Epidemiology. <i>Blood</i> , 2014, 124, 1822-1822. | 1.4 | 1 |
| 156 | Application of mTORC1 Inhibitors for Tissue-Agnostic Management of Standard-Therapy-Refractory Solid Tumors. <i>Cancers</i> , 2022, 14, 1936. | 3.7 | 1 |
| 157 | SELECTIVE REGRESSION OF LIVER TUMORS BY APOPTOSIS DUE TO AN INHERENT ACCELERATION OF CELL TURNOVER. <i>Biochemical Society Transactions</i> , 1996, 24, 606S-606S. | 3.4 | 0 |
| 158 | Co-occurrence of immature T-lymphoblastic lymphoma and acute myeloid leukemia – microenvironment-dependent lineage differentiation derived from a common progenitor?. <i>Journal of Hematopathology</i> , 2021, 14, 325-332. | 0.4 | 0 |
| 159 | HGG-44. DEFECTS OF MISMATCH REPAIR PROTEINS IN PEDIATRIC HIGH GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2020, 22, iii351-iii352. | 1.2 | 0 |
| 160 | Abstract P1-02-06: Prediction of Prosigna® breast cancer intrinsic subtype by immunohistochemical ER, PR and Ki67 expression. <i>Cancer Research</i> , 2022, 82, P1-02-06-P1-02-06. | 0.9 | 0 |
| 161 | PATH-09. Liquid biopsy of cerebrospinal fluid enables detecting and monitoring of MYC/MYCN amplification in pediatric CNS malignancies. <i>Neuro-Oncology</i> , 2022, 24, i160-i160. | 1.2 | 0 |